Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SNDX vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NUVB Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–1 Matrix Metrics)

NUVB Overall Winner 6-Pillar Tally: SNDX 3 – 3 NUVB Matrix Metrics: SNDX 1 – 6 NUVB

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Syndax Pharmaceuticals, Inc. (SNDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNDX carries a Unified Composite Score of 63.9/100 (BUY) at $8.72 (N/M Forward P/E, -61.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Composite vs. Pillar Nuance: While SNDX currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. NUVB 61.0/100 BUY), NUVB captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-61.2% vs. -61.7% operating margin) and revenue trajectory (+242.6% vs. +81.6% YoY).
  • Technical & Structure Timing Caution: SNDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SNDX vs NUVB
SNDX NASDAQ
Syndax Pharmaceuticals, Inc.
Pharmaceutical Preparations
$8.72
-4.49% 1D
Market Cap $822.0M
TTM Revenue $290M
Forward P/E N/M
Beta / 30D Vol 0.59β · 112% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 61.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.1%), weak momentum, RSI 28
RSI-14: 28.1 · SMA20: $10.91 · SMA50: $14.22
NUVB NYSE Head-to-Head Winner
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (SNDX 3 – 3 NUVB)

Columns: Metric · SNDX · NUVB
1. Valuation Multiples SNDX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 3.2x 7.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) +81.6% +242.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $290M $202M
Market Cap $822.0M $1.3B
3. Profitability & Quality NUVB
Gross Margin -2.0% 85.8%
Operating Margin -61.7% -61.2%
Net Profit Margin -72.3% -67.4%
Return on Equity (ROE) -426.4% -49.1%
4. Balance Sheet & Cash Flow NUVB
Cash Generation (TTM) -$177M -$108M
Cash Flow Margin -61.3% -53.6%
Net Cash / Leverage $109M Net Debt $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SNDX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 253.5% (41st %ile) 65.2% (26th %ile)
Put/Call OI Skew 0.09x (Call-Skewed) 0.24x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat SNDX
OpEx & R&D Intensity 59.7% of Rev ($173M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SNDX (1) vs NUVB (6)
Institutional Metric SNDX NUVB Criterion Row Edge
Market Capitalization
Scale
$822.0M $1.3B Larger Scale NUVB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+81.6% +242.6% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-61.7% -61.2% Higher Margin NUVB
Net Profit Margin
Profitability
-72.3% -67.4% Higher Margin NUVB
Return on Equity (ROE)
Capital Efficiency
-426.4% -49.1% Higher ROE NUVB
52-Week Range Position
Momentum
2% ($8–$26) 2% ($4–$10) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
0.59β · 112% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 61.0 / 100 (BUY) Higher Composite SNDX
Trailing 12M Revenue (USD)
Operating Scale
$290M $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-2.0% 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$177M ($109M Net Debt) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NUVB +16.59 pp
SNDX: -35.74% · NUVB: -19.15%
3M Horizon NUVB +11.65 pp
SNDX: -55.44% · NUVB: -43.79%
6M Horizon NUVB +36.78 pp
SNDX: -56.27% · NUVB: -19.49%
1Y Horizon NUVB +0.97 pp
SNDX: -47.82% · NUVB: -46.85%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SNDX Revenue NUVB Revenue SNDX Op. Margin NUVB Op. Margin Margin Leader
FY2016 $0M N/A -3587.4% N/A SNDX
FY2017 $0M N/A -2939.0% N/A SNDX
FY2018 $0M N/A -5001.7% N/A SNDX
FY2019 $0M N/A -3792.9% N/A SNDX
FY2020 $0M N/A -4708.2% N/A SNDX
FY2021 $140M N/A 18.8% N/A SNDX
FY2024 $20M $10M -1434.4% -7527.3% SNDX
FY2025 $170M $60M -158.4% -338.7% SNDX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SNDX BREAKDOWN
95d in phase · OBV DISTRIBUTION
Current IV 253.5%
IV Percentile 41st %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact SNDX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SNDX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $822.0M market capitalization and -61.7% operating margin.
OpEx & R&D Reinvestment 59.7% of Rev ($173M)
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SNDX vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Nuvation Bio Inc. (NUVB) is the stronger overall head-to-head candidate over Syndax Pharmaceuticals, Inc. (SNDX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SNDX carries a Unified Composite Score of 63.9/100 (BUY) at $8.72 (N/M Forward P/E, -61.7% operating margin), whereas NUVB carries 61.0/100 (BUY) at $3.80 (N/M Forward P/E, -61.2% operating margin). Composite vs. Pillar Nuance: While SNDX currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. NUVB 61.0/100 BUY), NUVB captures the overall institutional head-to-head verdict (6–1 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-61.2% vs. -61.7% operating margin) and revenue trajectory (+242.6% vs. +81.6% YoY). Technical & Structure Timing Caution: SNDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.1); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: SNDX posts +81.6% YoY revenue growth and +0.0% YoY earnings growth on $290M TTM revenue (-2.0% gross margin, -61.7% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), SNDX cumulative revenue shifted +21.4% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, SNDX deploys 59.7% of Rev ($173M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

SNDX screens cheaper on headline valuation multiples. SNDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (-61.3% FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SNDX (-426.4% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SNDX carries 253.5% implied volatility (41st %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.59β · 112% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.